Cochrane · systematic review · CD011626
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
Padhani, ZA, Gangwani, MK, Sadaf, A, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 5 · 71.4%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAmlodipine plus standard iron chelation therapy versus standard iron chelation therapy (alone or with placebo) for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
Population: or population: people with transfusion‐dependent beta thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiac T2* value Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 4 studies · 191 participants | Low Downgraded: risk of bias, imprecision |
MIC Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 3 studies · 138 participants | Low Downgraded: risk of bias, imprecision |
LVEF (echocardiography) Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 3 studies · 136 participants | Low Downgraded: risk of bias, imprecision |
Serum ferritin Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 4 studies · 187 participants | Low Downgraded: risk of bias, imprecision |
Liver T2* value Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 3 studies · 127 participants | Low Downgraded: risk of bias, imprecision |
LIC Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 2 studies · 123 participants | Moderate Downgraded: imprecision |
Adverse events Amlodipine plus standard iron chelation therapy vs standard iron chelation therapy (alone or with placebo) | no estimate extracted | 5 studies · 234 participants | Very low Downgraded: risk of bias, imprecision |
Amlodipine plus standard chelation therapy versus standard chelation therapy with or without placebo
Population: aged 6 years or older with transfusion‐dependent beta thalassaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in cardiac T2* (msec) Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 2 studies · 74 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Mean change in MIC (mg/g) Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 2 studies · 74 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Mean change in serum ferritin ng/mL Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 2 studies · 71 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Mean change in liver T2* (m/s) Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 2 studies · 74 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Mean change in LIC (mg/g) Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 1 study · 59 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Mean change in LVEF (%) Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | no estimate extracted | 2 studies · 72 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse events Amlodipine plus standard chelation therapy vs standard chelation therapy with or without placebo | RR 8.71 [0.49, 154.89] | 1 study · 59 participants | Low Downgraded: risk of bias, imprecision, indirectness |